About this trial
The researchers aim to investigate the outcome (overall survival) of mothers who are diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs, radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic examination).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Histologically proven cancer in association with a pregnancy (during pregnancy or cancer dagnosis within 5 years after pregnancy)
> 18 years of age, premenopausal
Patients who have given their signed and written informed consent to participate in the trial after fully understanding the implication of the protocol
Women receiving any cytotoxic drug or radiation therapy during pregnancy are allowed for the assessment of the maternal and fetal outcome (Part II).
Disqualifiers
Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent
Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent
Trial population
Premenopausal women with a cancer diagnosis in association with cancer
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Follow-up of the mothers diagnosed with cancer during pregnancy
treatment during pregnancy, obstetrical outcome, maternal survival
Follow-up of the children antenatally exposed to chemotherapy or radiotherapy
neurologic and cardiologic outcome
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Gasthuisberg
Lead sponsor
The Netherlands Cancer Institute
Collaborator
Erasmus Medical Center
Collaborator
San Gerardo Hospital
Collaborator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborator
Charles University, Czech Republic
Collaborator